Market Place
Sourcing Support
Zai Lab Shares Data on 3 In-House Oncology Drugs at AACR 2026
17 Mar 2026 //
BUSSINESSWIRE
Zai Lab To Unveil Q4 2025 Financials And Corporate Updates
10 Feb 2026 //
BUSINESSWIRE
Zai Lab Outlines Strategy, Global Pipeline at JPM 2026
13 Jan 2026 //
BUSINESSWIRE
Zai Lab To Present At J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Zai Lab Gets China Approval For Cobenfy In Schizophrenia
23 Dec 2025 //
BUSINESSWIRE
Zai Lab Updates China`s National Reimbursement Drug List
07 Dec 2025 //
BUSINESSWIRE
Zai Lab Unveils Q3 2025 Financials & Corporate Developments
06 Nov 2025 //
BUSINESSWIRE
Zai Lab To Attend Investor Conferences In Nov. & Dec. 2025
31 Oct 2025 //
BUSINESSWIRE
Zai Lab To Unveil Q3 2025 Financials And Corporate Updates
15 Oct 2025 //
BUSINESSWIRE
Zai Lab Announces Participation in Investor Conferences in Sept
28 Aug 2025 //
BUSINESSWIRE
Zai Lab Gets NMPA Innovative Device Nod For TTFields In Cancer
19 Aug 2025 //
BUSINESSWIRE
Zai Lab Forms Oncology Scientific Advisory Board
13 Aug 2025 //
BUSINESSWIRE
Zai Lab`s Q2 2025 Financial Results and Corporate Updates
07 Aug 2025 //
BUSINESSWIRE
Zai Lab to Announce Q2 2025 Results and Updates on August 7
10 Jul 2025 //
BUSINESSWIRE
Zai Lab and Novocure to Present PANOVA-3 Trial Results at ASCO
31 May 2025 //
BUSINESSWIRE
Zai Lab to Join Investor Conferences in June 2025
30 May 2025 //
BUSINESSWIRE
Zai Lab Reports Q1 2025 Financial Results and Corporate Updates
08 May 2025 //
BUSINESSWIRE
Zai Lab to Announce Q1 2025 Financial Results on May 8, 2025
14 Apr 2025 //
BUSINESSWIRE
Zai Lab to Join Investor Conferences in March 2025
03 Mar 2025 //
BUSINESSWIRE
Zai Lab Announces Q4 & Full Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
Zai Lab to Announce Q4 and Full Year 2024 Financial Results
28 Jan 2025 //
BUSINESSWIRE
Zai Lab`s NDA For KarXT Accepted For Schizophrenia Treatment
17 Jan 2025 //
BUSINESSWIRE
Vertex, Zai Lab Partner To Treat Autoimmune Diseases In Asia
10 Jan 2025 //
BIOSPECTRUM
Zai Lab To Join Investor Conference In January 2025
12 Dec 2024 //
BUSINESSWIRE
Zai Lab & Novocure Report Positive Results for Pancreatic Cancer
02 Dec 2024 //
BUSINESSWIRE
Zai Lab Announces Inclusion of AUGTYRO® for ROS1+ NSCLC in China
27 Nov 2024 //
BUSINESSWIRE
Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug
21 Nov 2024 //
BUSINESSWIRE
Zai Lab Announces Closing of Public Offering
18 Nov 2024 //
BUSINESSWIRE
Zai Lab Announces Pricing of Public Offering of ADS
14 Nov 2024 //
BUSINESSWIRE
Zai Lab Announces Public Offering of American Depositary Shares
13 Nov 2024 //
BUSINESSWIRE
Zai Lab Announces Q3 2024 Financial Results & Corporate Updates
12 Nov 2024 //
BUSINESSWIRE
Zai Lab Reports Positive Data for KarXT in Schizophrenia
29 Oct 2024 //
BUSINESSWIRE
Zai Lab To Participate In November, December Investor Conferences
18 Oct 2024 //
BUSINESSWIRE
Zai Lab To Announce Q3 2024 Financial Results On November 12
16 Oct 2024 //
BUSINESSWIRE
Zai Lab To Present ZL-1218 Data At ESMO Congress 2024
27 Aug 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in September Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Zai Lab Announces Second Quarter 2024 Financial Results and Corporate Updates
06 Aug 2024 //
BUSINESSWIRE
Argenx Reports H1 2024 Financials And Q2 Business Update
24 Jul 2024 //
GLOBENEWSWIRE
Zai Lab And Argenx Get China Approval For Efgartigimod In Myasthenia Gravis
16 Jul 2024 //
BUSINESSWIRE
Zai Lab Study In Cell Offers Insights On HRD-Positive Ovarian Cancer Treatment
15 Jul 2024 //
BUSINESSWIRE
Zai Lab To Announce Q2 2024 Results On August 6, 2024
10 Jul 2024 //
BUSINESSWIRE
Zai Lab: Reinhart Retiring, Amado New Global R&D Head
11 Jun 2024 //
BUSINESSWIRE
Zai Lab Initiates Global ZL-1102 Topical Psoriasis Phase 2
22 May 2024 //
BUSINESSWIRE
Zai Lab, Innoviva`s SUL-DUR Approved In China For Pneumonia
20 May 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in May and June Investor Conferences
16 May 2024 //
BUSINESSWIRE
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
13 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Zai Lab ROS1 NSCLC Drug AUGTYRO Approved In China
12 May 2024 //
BUSINESSWIRE
Zai Lab: Q1 2024 Financial Results, Corporate Updates
08 May 2024 //
BUSINESSWIRE
Zai Lab Q1 2024 Results, Updates On 5/8
15 Apr 2024 //
BUSINESSWIRE
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
11 Apr 2024 //
BUSINESSWIRE
Zai Lab Presentations at AACR 2024 Annual Meeting
02 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint
01 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner Novocure Announces METIS Ph 3 Trial Met Primary Endpoint
27 Mar 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in March Investor Conference
06 Mar 2024 //
BUSINESSWIRE
Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA
06 Mar 2024 //
BUSINESSWIRE
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
27 Feb 2024 //
BUSINESSWIRE
Zai Lab to Announce Full-Year 2023 Financial Results
25 Jan 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in January Investor Conference
19 Dec 2023 //
BUSINESSWIRE
Zai Lab Announces the First Listing of VYVGART and Other Updates
12 Dec 2023 //
BUSINESSWIRE
